Kawasaki Disease: A Distinctive and Dynamic Condition

Abstract

Kawasaki illness, an acute vasculitis of children, causes coronary artery aneurysms in approximately 25% of untreated patients. It has been reported globally and is the primary cause of acquired heart disease in children in developed countries. Fortunately, most individuals' cardiovascular health improves within a few months. Long-term complications of Kawasaki illness may include heart valve problems, unstable heartbeat rhythm, heart muscle inflammation, and aneurysms (bulges in blood vessels). It most commonly affects newborns and early children. There is a rash and fever in the early stages. Peeling skin and a high temperature are among the symptoms. Vasculitis, or inflammation of medium-sized blood vessels, may occur later. It also affects skin, mucous membranes, including those inside the mouth, and lymph nodes. Most of the time, Kawasaki disease is curable. Aspirin and intravenous immunoglobulin therapy administered in a medical setting are examples of initial therapies. Most cases of systemic vasculitis, or KD, are in youngsters. The geography and seasonality of a disease have an impact on its epidemiology. Even though it has been many years since the initial report on KD, several linked aspects remain unknown. Acute systemic vasculitis, known as Kawasaki illness, was initially documented in 1961. Many papers have been published in the previous fifty years to help us understand this condition better. Clinical findings are used to diagnose Kawasaki disease. Patients with atypical Kawasaki illness include those who do not fit all diagnostic requirements. Intravenous immunoglobulin and aspirin are used to treat coronary aneurysms, the primary consequence of Kawasaki illness. If the patient does not improve, a second dosage of immunoglobulin is administered. Several different second and third-line therapeutic options have been suggested in the past few years.